OOIR: Observatory of International Research

Papers

(The TQCC of Clinical & Translational Immunology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
	42
	37
Biomarkers to predict and diagnose pulmonary complications in children post haematopoietic stem cell transplant	28
Circulating cytokine and chemokine patterns associated with cytomegalovirus reactivation after stem cell transplantation	27
SARS‐CoV‐2‐associated T‐cell infiltration in the central nervous system	25
Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis	22
Spatial omics for profiling the dynamic tumor microenvironment	21
The spectrum of B cells in the pathogenesis, diagnosis and therapeutic applications of immunoglobulin G4‐related disease	19
Characteristics of PD‐1⁺CD4⁺ T cells in peripheral blood and synovium of rheumatoid arthritis patients	19
Polyfunctional T peripheral helper cells are associated with the magnitude and durability of antibody responses after COVID‐19	18
An optimised whole blood interleukin‐2 release assay is more sensitive than interferon‐γ ELIS pot for detecting and quantifying gluten‐specific	16
Targeting BMI‐1 to deplete antibody‐secreting cells in autoimmunity	14
	14
	14
	14
The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation	13
Effects of extremely preterm birth on cytokine and chemokine responses induced by T‐cell activation during infancy	13
Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma	12
Adeno‐associated viral vectors encoding anti‐P2X7 nanobodies reduce graft‐versus‐host disease in a humanised mouse model	12
Optimised modular anti‐FLAG CAR T cells for solid tumor therapy	10
	10
Adaptive immune response to the autoantigen LL ‐37 differentiates atherosclerotic cardiovascular disease phenotypes	10
Mass cytometry analysis reveals altered immune profiles in patients with coronary artery disease	10
Siglec‐1, an easy and contributory inflammation marker in rheumatology	10
Naturally acquired adaptive immunity to Streptococcus pneumoniae is impaired in rheumatoid arthritis patients	9

Inhibitory effect of hydroxychloroquine on glucocorticoid‐induced osteoporosis in lupus therapy	9
Immunological insights into gastric polyps: pathogenesis, inflammation and neoplastic potential	9
Genome‐wide association study and polygenic risk scores of eosinophilia in Taiwan	9
	8
	8
Data standards for single‐cell RNA ‐sequencing of paediatric cancer	8
High KRT17 expression in tumour budding indicates immunologically ‘hot’ tumour budding and predicts good survival in patients with colorectal cancer	8
Skin immunity and inflammation: cellular interactions and communication	8
	8
Robust immunity to influenza vaccination in haematopoietic stem cell transplant recipients following reconstitution of humoral and adaptive immunity	8
	8
Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models	8
Human axillary lymph node T follicular helper (Tfh) and Precursor‐Tfh cells exhibit functional flexibility following seasonal influenza vaccination	8
Hypoxia‐inducible factor‐1α regulates the interleukin‐6 production by B cells in rheumatoid arthritis	7
CD39 expression defines exhausted CD4⁺ T cells associated with poor survival and immune evasion in human gastric cancer	7
Helminths as architects of trained tolerance: implications for human health	7
	7
A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies	7
Prediction of intravenous immunoglobulin retreatment in children with Kawasaki disease using models combining lymphocyte subset and cytokine profile in an East Asian cohort	7
A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non‐small‐cell	6
The impact of B‐cell reconstitution on mRNA vaccine responses in allogeneic stem cell transplant recipients	6
	6
Long‐term effects of influenza and Bacille Calmette–Guérin vaccination on systemic inflammation	6
Fatty acid metabolism—an emerging regulatory node in T‐cell immunometabolism	6
Pulmonary complications post allogeneic haematopoietic stem cell transplant in children	6
A unique cytotoxic CD4 ⁺ T cell‐signature defines critical COVID‐19	6
Infiltrating characteristics and prognostic value of tertiary lymphoid structures in resected gastric neuroendocrine neoplasm patients	6
Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis	6
	6
Neutralising antibody responses to emerging SARS ‐ CoV ‐2 omicron sub‐variants are enhanced in per	6
Administration of an LXR agonist promotes atherosclerotic lesion remodelling in murine inflammatory arthritis	5
Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival	5
Elucidating novel immune profiles for predicting infection in high‐risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia	5
Adoptive T‐cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis	5
Serological responses and clinical outcomes following a three‐dose primary COVID‐19 vaccine schedule in kidney transplant recipients and people on dialysis	5
Multi‐omics integration reveals a nonlinear signature that precedes progression of lung fibrosis	5
	5
	5
Graft CD8 T‐cell‐based risk system predicts survival in antithymocyte globulin‐based myeloablative haploidentical peripheral blood stem cell transplantation	5
Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2 and COVID‐19 vaccination	5